Rewalk Robotics Ltd
NASDAQ:LFWD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Rewalk Robotics Ltd
NASDAQ:LFWD
|
IL |
|
B
|
Bowim SA
WSE:BOW
|
PL |
|
Galapagos NV
AEX:GLPG
|
BE |
|
Shanghai LongYun Cultural Creation & Technology Group Co Ltd
SSE:603729
|
CN |
|
Sunkwan Properties Group Ltd
HKEX:6900
|
CN |
|
Chelyabinskiy Metallurgicheskiy Kombinat PAO
MOEX:CHMK
|
RU |
|
M
|
MST Golf Group Bhd
KLSE:MSTGOLF
|
MY |
|
Groupe Gorge SA
OTC:GGRGF
|
FR |
Rewalk Robotics Ltd
ReWalk Robotics Ltd. Is a medical device company, which engages in the design, development and marketing of wearable robotic exoskeletons. The firm is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The firm offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. ReWalk designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The firm offers two ReWalk products: ReWalk Personal and ReWalk Rehabilitation. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities, and is custom fitted for each user. ReWalk Rehabilitation is designed for use by paraplegia patients in the clinical rehabilitation environment, where it provides exercise and therapy.
ReWalk Robotics Ltd. Is a medical device company, which engages in the design, development and marketing of wearable robotic exoskeletons. The firm is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The firm offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. ReWalk designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The firm offers two ReWalk products: ReWalk Personal and ReWalk Rehabilitation. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities, and is custom fitted for each user. ReWalk Rehabilitation is designed for use by paraplegia patients in the clinical rehabilitation environment, where it provides exercise and therapy.
Strategic partnership: Lifeward closed shareholder approval for a strategic transaction with Oramed, which will provide capital and access to ORMP-0801, an oral insulin candidate the company views as a high-upside biotech asset.
Revenue miss: 2025 revenue was $22.0 million, down from $25.7 million in 2024; management cited a distributor timing issue for AlterG and a sales-channel transition as the main causes.
Commercial reset: Management restructured sales into three focused channels (direct-to-patient, capital equipment, and payer engagement) and highlighted recent Medicare Advantage coverage wins with Aetna, Humana and UnitedHealthcare (16 million covered lives).
Product expansion: Lifeward acquired IP and the engineering team from Skelable for a powered upper-extremity exoskeleton; management expects a relatively low-barrier regulatory path and a commercialization timeline of roughly 18–24 months.
Improving profitability trends: Operating loss narrowed to $19.7 million and net loss to $19.9 million in 2025; operating cash usage fell to $16.8 million, and the company secured a $3.0 million loan from Oramed with an expected $10.0 million convertible note upon close.
No guidance: Given the transformation and pending Oramed close, Lifeward will not provide 2026 guidance at this time.
Commercial momentum signals: ReWalk units sold increased 22% YoY despite flat ReWalk revenue ($8.5 million), and the U.S. ReWalk pipeline had 104 qualified leads at year-end.
